Evidence map›Paper›PMID 10221598›Full record

ArticleEndocrine1998

Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells.

J S Krumenacker, D W Montgomery, D J Buckley, P W Gout, A R Buckley

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. The prolactin receptor: Diverse and emerging roles in pathophysiology.Journal of clinical & translational endocrinology · 2015
    Review
  4. Article
  5. Review
  6. Article
  7. Regulatory and signaling properties of the Vav family.Molecular and cellular biology · 2000
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

J S KrumenackerDepartment of Pharmacology and Toxicology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, USA.
D W Montgomery
D J Buckley
P W Gout
A R Buckley
University of North Dakota · USBC Cancer Agency · CASouthern Arizona VA Health Care System · USUniversity of Arizona · US

Funding

PROLACTIN INHIBITION OF APOPTOSIS--MECHANISM OF ACTIONR01DK053452 · NIDDK · UNIVERSITY OF NORTH DAKOTA · PI BUCKLEY, ARTHUR R · 1998 to 2001
$382k
NUCLEAR PROLACTIN RECEPTORS: REGULATION OF TRANSCRIPTIONR29DK044439 · NIDDK · UNIVERSITY OF NORTH DAKOTA · PI BUCKLEY, ARTHUR R · 1992 to 1997
–
NIDDK NIH HHS DK44439NIDDK NIH HHS DK53452
6 · The paper itself

Abstract

Previously, we reported that activation of the human prolactin receptor (PRLR) produced a protein phosphorylation pattern strikingly similar to that provoked by Concanavalin A (Con A), an activator of the T-cell antigen receptor (TCR). These results suggested that certain signaling components of the TCR may be shared by the activated PRLR. Additional studies here assessed the levels of TCR expression following PRLR stimulation and the effect of TCR activation on PRL-stimulated proliferation in lactogen-dependent pre-T Nb2-11 lymphoma cells. The results indicated that the TCR was expressed on the surface of approx 4% of exponentially proliferating and prolactin- (PRL) treated cells. In contrast, approx 45% of quiescent cells, cultured in the absence of PRL for 24 h, expressed the TCR at the cell surface, suggesting that lactogen withdrawal may up-regulate TCR cell-surface expression. Moreover, TCR activation with anti-CD3 antibodies attenuated PRL-stimulated Nb2-11 cell proliferation in a concentration-dependent manner. In other experiments, immunoprecipitation and immunoblotting of Nb2-11 lysates revealed that activation of the PRLR resulted in rapid tyrosyl phosphorylation of ZAP-70, a critical TCR-associated tyrosine kinase. In addition, ZAP-70 was found to associate transiently with the putative guanine nucleotide exchange factor and substrate, Vav, in PRL-treated cells. ZAP-70 was also found to associate constitutively with the PRLR; PRL stimulation provoked the transient recruitment of Vav to the complex. These observations suggest that PRL signaling reflects the transient formation of a PRLR-ZAP-70-Vav complex and its immunomodulatory actions involve diverse interactions that affect TCR expression and signaling mechanisms.

Indexed as

Cell Cycle ProteinsSignal TransductionCD3 ComplexHumansLymphoma, T-CellMacromolecular SubstancesPhosphorylationProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-vavReceptors, Antigen, T-CellReceptors, ProlactinTumor Cells, CulturedTyrosineZAP-70 Protein-Tyrosine KinaseCD3 ComplexCell Cycle ProteinsMacromolecular SubstancesProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-vavReceptors, Antigen, T-CellReceptors, ProlactinTyrosineVAV1 protein, humanZAP70 protein, humanZAP-70 Protein-Tyrosine Kinase

Identifiers

PMID10221598
OpenAlexW2003543806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.